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Although differing only for the last 24 aminoacids, the three major isoforms of  p21 Ras (Ha-, Ki- 
and N –Ras) can trigger alternative pathways of signal transduction, at least in part as a 
consequence of different post-translational modifications and subcellular localization. Ras 
mutations are  a common event in tumorigenesis. In colorectal carcinomas (CRCs) the mutations 
affect almost exclusively Ki-Ras, while Ha-Ras mutations are mostly found in bladder carcinomas 
and N-Ras mutations in leukemia cells. In almost all cases, the genetic alteration is a point mutation 
in codons 12 or 13, and less frequently in codon 61. By affecting the GTPase activity of the protein, 
they always lead to a constitutively active protein. However, data obtained in different experimental 
systems or by analysis of primary and metastatic tumors show that not only mutations of different 
isoforms of Ras, but also mutations in different codons or different mutations in the same codon of 
the same isoform of Ras may have diverse biological consequences. To shed more light on the 
molecular mechanisms responsible for the different effects of Ras mutations, we have obtained 
stable clones of HT-29 (a human colorectal adenocarcinoma cell line in which the endogenous Ras 
genes are wild type) transfected with cDNAs codifying Ha-RasG12V, Ki-RasG12V and Ki-
RasG13D, under the control of an hormone-inducible promoter. We found that the expression of 
each of these mutated Ras isoforms induces specific, different effects on cell morphology and 
growth rate. FACS analysis shows also a differential effect on the cell cycle. H-RasG12V 
expression, in addition, induces apoptosis, through caspase activation mediated by p53 independent, 
MEK-1 dependent expression of the CDK inhibitor p21.  
 
 
 
 
 
 
